The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure. * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on lung function than delivery of NAC without positive pressure. Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group or the NAC via AeroEclipse-VersaPAP nebulizer group. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the nebulization method specific to their group.
Sponsor: University of California, San Francisco
You may qualify if…
- ✓ Asthma Group:
- ✓ 1. Male or female between the ages of 18 to 85 at Visit 1
- ✓ 2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
- ✓ 3. Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria
- ✓ 4. Clinical history of asthma per patient report or medical record
- ✓ 5. Asthma requiring treatment with inhaled corticosteroids (ICS) or biologic therapy for 3 months or greater
- ✓ 6. Computed Tomography (CT) mucus score ≥ 3 (done as part of screening)
- ✓ 7. There is no lower threshold on Forced Expiratory Volume in the first second (FEV1), which means the study will attempt to enroll all patients regardless of asthma severity. However, eligible participants will need to demonstrate ability to tolerate study treatment reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1. Participants who have a \>20% drop in FEV1 after receiving any study treatment will be excluded from the study.
You may not qualify if…
- ✕ 1. A history of medical disease, which in the opinion of the investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study.
- ✕ 2. Currently pregnant
- ✕ 3. URI in past 10 days
Where it's recruiting
San Francisco
Source: ClinicalTrials.gov · NCT06152653 · last updated 2025-07-30